However, these surface molecules have been shown to dynamically vary in expression during disease states (e.g., EMT)28, 29, are not present on certain types of cancer cells such as those associated with melanoma, and patient CTCs typically express fewer copies of EpCAM than cancer cell lines typically used to validate new CTC technologies30. This evidence concerns the gene EPCAM and melanoma.